SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Banner. Contemporary art collage. Charity or alms. Person handing single coin to another person. Grainy fabric effect. Concept of business, financial literacy, debts, banking, salary. Ad
Series B
Adcendo Rides ADC Wave With $135M Series B
Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.
November 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Front view of the CDC museum in Georgia
Government
Trump Picks Vaccine Critic Weldon to Lead CDC, Makary for FDA Head
Career conservative and former congressman Dave Weldon will, if confirmed, act as director of the Centers of Disease Control and Prevention, where his anti-vaccine views will mesh with those of selected Department of Health and Human Services head Robert F. Kennedy Jr.
November 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Business investment or risk, high-risk investment, risk-taking, businessmen walking a tightrope across a crocodile area
Editorial
Embattled Sage Dealt Deeper Blow With Huntington’s Failure
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts to question the biotech’s future profitability.
November 25, 2024
 · 
4 min read
 · 
Heather McKenzie
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Applied Therapeutics Awaits Verdict on Rare Disease Therapy
With two decisions originally scheduled for this week already announced, including BridgeBio’s approval in ATTR-CM, the regulator has just one PDUFA on its plate this holiday week.
November 25, 2024
 · 
1 min read
 · 
Tristan Manalac
Concept image of an anticancer drug called ADC. 3d rendering
Antibody-drug conjugate
Next-Gen ADCs Driving ‘Renaissance’ in Already Hot Oncology Drug Class
ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and toxicity challenges of current ADCs—and rapidly grow the multibillion-dollar market.
November 25, 2024
 · 
7 min read
 · 
Greg Slabodkin
Heart human anatomy anatomical pottery neutral backgrounds soft tones beige brown background 3d illustration render digital rendering
Drug Development
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against Pfizer’s tafamidis and potentially Alnylam’s Amvuttra.
November 23, 2024
 · 
8 min read
 · 
Heather McKenzie
Man lurrking behind the american flag. USA default, financial crisis, political problems concept. Flat vector illustration.
Editorial
Trump’s ‘Team of Self Promoters’ Will Make for Great Reality TV but an Uncertain Biopharma Environment
RFK Jr. as HHS head is perhaps President-elect Donald Trump’s most controversial Cabinet pick now that Matt Gaetz has withdrawn as nominee for Attorney General. With Dr. Oz tapped to lead CMS and maybe Marty Makary at the FDA, it’s going to be quite the show.
November 22, 2024
 · 
6 min read
 · 
Jef Akst
MRI scans of a human brain
Postmarket research
Merck’s Former Asthma Blockbuster Singulair Could Be Linked to Mental Health Problems: Reuters
A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma therapy montelukast to adverse neuropsychiatric effects.
November 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Gene therapy
Patient Death in Rett Syndrome Trial Forces Neurogene to Drop High-Dose Arm
Despite the death, the FDA has allowed Neurogene to forge ahead with the Phase I/II Rett syndrome trial, but using only the lower 1E15 vg dose of its investigational gene therapy NGN-401.
November 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS